Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Translational Andrology and Urology|May 10, 2021
Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancerEdmond M Kwan, Heidi Fettke, Megan Crumbaker, et al.
Cancers|October 13, 2021
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate CancerHui-Ming Lin, Nicole Yeung, Jordan F Hastings, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 16, 2010
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and developmentTina Bianco-Miotto, Karen Chiam, Grant Buchanan, et al.
Asia-Pacific Journal of Clinical Oncology|February 8, 2022
Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statementsEdmund Chiong, Declan G Murphy, Nicholas C Buchan, et al.
BMC Medicine|March 25, 2022
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancerBlossom Mak, Hui-Ming Lin, Edmond M Kwan, et al.
Oncoimmunology|July 30, 2016
CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responsesPhillip D Fromm, Michael S Papadimitrious, Jennifer L Hsu, et al.
Cancer Research|August 7, 2021
Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid CompositionLisa M Butler, Chui Yan Mah, Jelle Machiels, et al.
The Lancet. Oncology|April 2, 2026
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 studyShahneen Sandhu, Anthony M Joshua, Louise Emmett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate CancerTanya Dorff, Lisa G Horvath, Karen Autio, et al.
JCO Precision Oncology|July 8, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III TrialsChristopher J Sweeney, Vrishab Krishna, Viswesh Krishna, et al.
Pageof 13